Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. reports developments as a clinical-stage global biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory and autoimmune diseases. Company news commonly covers quarterly financial results, pipeline updates, clinical program strategy, data presentations and changes in research priorities across its investigational portfolio.
Recurring updates focus on casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer, and earlier inflammation programs such as AB102, an MRGPRX2 antagonist. Arcus also issues routine corporate announcements on employment inducement grants, investor conference participation and collaboration-related developments.
Arcus Biosciences (NYSE:RCUS) announced the return of Jennifer Jarrett as Chief Operating Officer, overseeing commercial and administrative operations. Jarrett, who previously helped lead the company's IPO, brings extensive experience in healthcare and finance. CEO Terry Rosen emphasized her role in facilitating Arcus's mission to develop transformative cancer therapies, especially with three molecules potentially entering registrational trials. In conjunction with her appointment, Jarrett received options to purchase 900,000 shares at $17.17 each, part of an inducement grant approved by the board.